Compare VanEck Junior Gold Miners (GDXJ) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Junior Gold Miners vs Zimmer Biomet Holdings Inc — how do they compare? VanEck Junior Gold Miners trades at $114.43 (market cap $8.22B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 2.1× VanEck Junior Gold Miners's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while VanEck Junior Gold Miners pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Junior Gold Miners for 41 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| GDXJ | ZBH | |
|---|---|---|
Market Cap | $8.22B | $16.95B |
Volume | 3,212,198 | 2,505,240 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $156.19 | $103.98 |
52-Week Low | $87.56 | $79.58 |
Typical Hold Time | 41 Days | 89 Days |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDXJ, the VanEck Junior Gold Miners ETF, trades at $110.91, up 1.62% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. Recent news highlights multiple junior gold mining companies being added to the ETF, potentially increasing its diversification and appeal. Key financial ratios are not applicable as this is an ETF tracking an index of companies.
The outlook for GDXJ is influenced by gold price volatility and the performance of its underlying junior mining holdings. Opportunities exist if gold prices rise, boosting miner profitability, but risks include operational challenges and market sentiment shifts. Investors should weigh exposure to small-cap miners against broader market conditions.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Junior Gold Miners
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
